Lifeboat Foundation

A team of researchers from Illinois Institute of Technology and the University of Washington is trying to change the way that the field of biology understands how muscles contract.

In a paper published on January 25, 2023, in the Proceedings of the National Academy of Sciences titled “Structural OFF/ON Transition of Myosin in Related Porcine Myocardium Predict Calcium Activated Force,” Illinois Tech Research Assistant Professor Weikang Ma and Professor of Biology and Physics Thomas Irving—working in collaboration with Professor of Bioengineering Michael Regnier’s group at Washington—make the case for a second, newly discovered aspect to muscle contraction that could play a significant role in developing treatments for inherited cardiac conditions.

The consensus for how muscle contraction occurs has been that the relationship between the thin and thick filaments that comprise muscle tissue was a more straightforward process. When targets on thin filaments were activated, it was thought that the myosin motor proteins that make up the thick filaments would automatically find their way to those thin filaments to start generating force and contract the muscle.

Cancer vaccines are an active area of research for many labs, but the approach that Shah and his colleagues have taken is distinct. Instead of using inactivated tumor cells, the team repurposes living tumor cells, which possess an unusual feature. Like homing pigeons returning to roost, living tumor cells will travel long distances across the brain to return to the site of their fellow tumor cells. Taking advantage of this unique property, Shah’s team engineered living tumor cells using the gene editing tool CRISPR-Cas9 and repurposed them to release tumor cell killing agents. In addition, the engineered tumor cells were designed to express factors that would make them easy for the immune system to spot, tag, and remember, priming the immune system for a long-term anti-tumor response.

The team tested their repurposed CRISPR-enhanced and reverse-engineered therapeutic tumor cells (ThTC) in different mice strains, including the one that bore bone marrow, liver, and thymus cells derived from humans, mimicking the human immune microenvironment. Shah’s team also built a two-layered safety switch into the cancer cell, which, when activated, eradicates ThTCs if needed. This dual-action cell therapy was safe, applicable, and efficacious in these models, suggesting a roadmap toward therapy. While further testing and development is needed, Shah’s team specifically chose this model and used human cells to smooth the path of translating their findings for patient settings.

But every once in a while, an idea is so powerful and so profound its effects are felt much faster.

That’s been the case with CRISPR gene editing, which celebrates a 10th anniversary this month. It has already had a substantial impact on laboratory science, improving precision and speeding research, and it has led to clinical trials for a handful of rare diseases and cancers.

Over the next decade, scientists predict, CRISPR will yield multiple approved medical treatments and be used to modify crops, making them more productive and resistant to disease and climate change.

CRISPR gene editing created the G795A amino acid which was introduced to microglia derived from human stem cells. Researchers were able to transplant the donor microglia immune cells into humanized rodent models while administering an FDA-approved cancer drug called pexidartinib. The inclusion of the amino acid cause the donated microglia to thrive and resist the drug, while the host microglia died. The findings open the door for new methods of using microglia to treat a range of neurodegenerative disorders.

Researchers have been working for many years to comprehend the relationship between brain structure, functional connectivity, and intelligence. A recent study provides the most comprehensive understanding to date of how different regions of the brain and neural networks contribute to a person’s problem-solving ability in a variety of contexts, a trait known as general intelligence.

The researchers recently published their findings in the journal Human Brain Mapping.

The research, led by Aron Barbey, a professor of psychology, bioengineering, and neuroscience at the University of Illinois Urbana-Champaign, and first author Evan Anderson, a researcher for Ball Aerospace and Technologies Corp. working at the Air Force Research Laboratory, employed the technique of “connectome-based predictive modeling” to evaluate five theories on how the brain leads to intelligence.

I never thought I’d order live human kidney cells to my address, but that all changed when I found out about biohacker Jo Zayner’s at-home genetic engineering class.

You may know Jo Zayner, a “biohacker” who has been in the vanguard of scientific self-experimentation for years, from their role in Netflix’s 2019 docuseries Unnatural Selection. The series shows Zayner attempting to edit their DNA by injecting themselves with CRISPR, a gene-editing technology. The action inspired a firestorm of criticism.

Zayner is also known for a variety of other bold moves, such as claiming to create a DIY at-home COVID vaccine in 2020 and executing their own fecal microbiome transplant.

On Nov. 26, 2022 a SpaceX Falcon 9 rocket departed from departed from NASA’s Kennedy Space Center in Florida to deliver supplies to the International Space Station. Among the 7,700 pounds of cargo on board, it is safe to say that the smallest delivery that day were a bunch of frozen bacteria.

In an interdisciplinary collaboration, a group of scientists from MIT Media Lab, NREL, Seed Health and others, bioengineered a plastic-eating bacteria to be able to upcycle plastics. Mashable met with some of them to find out how the bacteria works, why it was it was sent to space, and how it can help humanity tackle plastic pollution in space as well as on Earth.

Continue reading “Why Are We Sending a Plastic-Eating Enzyme to Space? | Mashable” »

You’ve seen the headlines. The FDA approved its use in tackling the underlying genetic mutation for sickle cell disease. Some researchers edited immune cells to fight untreatable blood cancers in children. Others took pig-to-human organ transplants from dream to reality in an attempt to alleviate the shortage of donor organs. Recent work aims to help millions of people with high cholesterol—and potentially bring CRISPR-based gene therapy to the masses—by lowering their chances of heart disease with a single injection.

But to Dr. Jennifer Doudna, who won the Nobel Prize in 2020 for her role in developing CRISPR, we’re just scratching the surface of its potential. Together with graduate student Joy Wang, Doudna laid out a roadmap for the technology’s next decade in an article in Science.

If the 2010s were focused on establishing the CRISPR toolbox and proving its effectiveness, this decade is when the technology reaches its full potential. From CRISPR-based therapies and large-scale screens for disease diagnostics to engineering high-yield crops and nutritious foods, the technology “and its potential impact are still in their early stages,” the authors wrote.

MIT neuroscientists have found that the adult brain is filled with millions of “silent synapses” — immature connections between neurons that are not active until they are needed to help create new memories.

It was previously believed that silent synapses only existed during early development, playing a role in helping the brain learn new information encountered in early life. However, the new MIT

MIT is an acronym for the Massachusetts Institute of Technology. It is a prestigious private research university in Cambridge, Massachusetts that was founded in 1861. It is organized into five Schools: architecture and planning; engineering; humanities, arts, and social sciences; management; and science. MIT’s impact includes many scientific breakthroughs and technological advances. Their stated goal is to make a better world through education, research, and innovation.